Key result
Dipyridamole administration in normal subjects demonstrated a terminal half-life of 11.6 +/- 2.2 hours and oral systemic availability of 43 +/- 13%, suggesting widely varying concentrations.
Why the study?
What are the pharmacokinetic properties of intravenous and oral dipyridamole in healthy subjects?
Population
6 normal subjects (3 men and 3 women), ages 22 to 34 years old.
Design
Other
Follow-up
3 days
Authors
Loading...
Variable bioavailability cautions against empirical dosing; leaves open validation of individualized regimens in patients.
What are the pharmacokinetic properties of intravenous and oral dipyridamole in healthy subjects?
Dipyridamole exhibits widely varying concentrations and a systemic oral availability of 43%, raising questions about the clinical practice of using empirical dosage schedules.
Mahony et al. (1982) studied Healthy (n=6). Dipyridamole was evaluated on Dipyridamole kinetics (terminal half-life, clearance, volume of distribution, systemic availability). Dipyridamole administration in normal subjects demonstrated a terminal half-life of 11.6 +/- 2.2 hours and oral systemic availability of 43 +/- 13%, suggesting widely varying concentrations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: